Perceptive Advisors logo

Perceptive Advisors

Crunchbase
Pitchbook
Crunchbase

Deals on record

7

Common Fundraising Type

Series B

Kardigan logo
Kardigan

Biopharmaceutical

Perceptive Advisors logo
Sequoia Heritage logo
ARCH Venture Partners logo

Kardigan is a biopharmaceutical company developing personalized medicines for cardiovascular diseases using a proprietary R&D platform.

Series A
$300M
01/10/2025
Article
Beta Bionics logo
Beta Bionics

Medical Technology

Wellington Management logo
RTW Investments logo
Soleus Capital logo
Sands Capital logo
Perceptive Advisors logo
Omega Funds logo
Marshall Wace logo
Eventide Asset Management logo

Beta Bionics is a medical technology company that designs, develops, and commercializes autonomous insulin delivery systems to streamline diabetes management.

Series E
$60M
11/15/2024
Article

Zucara Therapeutics Inc. is a life sciences company developing treatments to prevent hypoglycemia in diabetes patients.

Series B
$20M
11/12/2024
Article
Axonis Therapeutics logo
Axonis Therapeutics

Biotechnology

venBio Partners logo
Sofinnova Investments logo
Solasta Ventures logo
SCI Ventures logo
Tachyon Ventures logo
Perceptive Advisors logo
MRL Ventures Fund logo
Lumira Ventures logo

Axonis Therapeutics is a biotechnology company developing novel neuromedicines targeting neurological disorders like epilepsy and pain.

Series A
$115M
10/30/2024
Article

Orpyx Medical Technologies develops advanced sensory insoles that use multi-modal sensor technology for continuous remote monitoring to prevent diabetic foot ulcers and amputations.

Equity
$20M
09/25/2024
Article
Beta Bionics logo
Beta Bionics

Medical Technology

Soleus Capital logo
Sands Capital logo
RTW Investments logo
Pura Vida Investments logo
Perceptive Advisors logo
Omega Funds logo
Marshall Wace logo
Farallon Capital logo

Beta Bionics is a medical technology company that designs, develops, and commercializes autonomous insulin delivery systems to streamline diabetes management.

Series D
$100M
09/01/2023
Article

Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.

Series B
$150M
08/23/2023
Article